A Pilot and Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Intraoperative Detection of Occult Ovarian Carcinoma
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2018
Price : $35 *
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Ovarian cancer
- Focus Pharmacodynamics
- 01 Jun 2018 Status changed from active, no longer recruiting to completed.
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Feb 2018, according to ClinicalTrials.gov record.